Target intelligence / Profile preview

Vaginal microbiota (VM) (VM)

Target
VM
Molecular classification
Microbiome, Bacterial Community, Commensal and Pathogenic Bacteria
01

Overview

The vaginal microbiota is a complex biological community consisting of various microorganisms, predominantly bacteria, that inhabit the vaginal environment. In healthy individuals of reproductive age, the microbiota is typically dominated by Lactobacillus species, which play a critical role in maintaining vaginal health by producing lactic acid, lowering the pH to below 4.5, and secreting antimicrobial compounds [Ravel et al., 2011, PNAS]. This acidic environment serves as a primary defense mechanism against the colonization and overgrowth of pathogenic organisms, including those responsible for sexually transmitted infections and urinary tract infections [Coudray & Madhivanan, 2020, Eur J Obstet Gynecol Reprod Biol]. When the balance of this ecosystem is disrupted—a state known as dysbiosis—pathogenic anaerobic bacteria such as Gardnerella vaginalis and Atopobium vaginae proliferate, leading to bacterial vaginosis (BV) and increasing the risk of adverse pregnancy outcomes like preterm birth [Fettweis et al., 2019, Nature Medicine]. Therapeutic interventions target this community either through the use of broad-spectrum or targeted antibiotics to eliminate pathogens or through the administration of live biotherapeutic products (probiotics) to restore the dominance of beneficial Lactobacillus strains [Cohen et al., 2020, NEJM]. Understanding the dynamics of the vaginal microbiota is essential for developing precision medicine approaches to women's reproductive health and infectious disease management [Redelinghuys et al., 2020, Front Cell Infect Microbiol].

Other names
Vaginal microbiomeVaginal floraVaginal bacterial communityVaginal microflora
02

Mechanism of action

Antibiotics such as metronidazole and tinidazole act by being reduced within anaerobic bacteria to form reactive intermediates that disrupt DNA [StatPearls]. Clindamycin inhibits bacterial protein synthesis by binding to the 50S ribosomal subunit [PubMed]. Live biotherapeutic products, such as Lactobacillus crispatus CTV-05, work through competitive exclusion, production of lactic acid to maintain a low pH, and secretion of hydrogen peroxide and bacteriocins to inhibit pathogenic growth [NEJM].

03

Biological functions

Lactic acid production and pH regulation [PNAS]Pathogen inhibition via bacteriocins [Nature]Immune system modulation [Frontiers]Epithelial barrier maintenance [PubMed]
04

Disease associations

Bacterial vaginosis [StatPearls]Vulvovaginal candidiasis [PubMed]Preterm birth [Nature Medicine]Increased susceptibility to HIV and other STIs [NIH]Pelvic inflammatory disease [CDC]
05

Safety considerations

Development of antimicrobial resistance [PubMed]Secondary vulvovaginal candidiasis due to depletion of protective flora [StatPearls]High rates of recurrence following cessation of antibiotic therapy [Nature Reviews Microbiology]Potential for systemic absorption of topical agents [FDA]
06

Interacting drugs

Metronidazole

5 more in the full profile.

07

Biomarkers

Nugent score (Gram stain evaluation) [PubMed]Amsel criteria (clinical markers) [StatPearls]Vaginal pH > 4.5 [NIH]16S rRNA gene sequencing for Community State Types (CSTs) [PNAS]Presence of clue cells [StatPearls]

Beyond the preview

Go deeper on Vaginal microbiota (VM) (VM).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Full profile access

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Full profile access

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Full profile access

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Full profile access

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Full profile access

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Full profile access

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Vaginal microbiota (VM) (VM).

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call